Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.

Lindsay CR, Shaw EC, Blackhall F, Blyth KG, Brenton JD, Chaturvedi A, Clarke N, Dick C, Evans TRJ, Hall G, Hanby AM, Harrison DJ, Johnston SRD, Mason MD, Morton D, Newton-Bishop J, Nicholson AG, Oien KA, Popat S, Rassl D, Sharpe R, Taniere P, Walker I, Wallace WA, West NP, Butler R, Gonzalez de Castro D, Griffiths M, Johnson PWM.

ESMO Open. 2018 Sep 5;3(6):e000408. doi: 10.1136/esmoopen-2018-000408. eCollection 2018.

2.

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available.

PMID:
30032243
3.

Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.

Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.

J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.

PMID:
30006425
4.

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.

Simigdala N, Pancholi S, Ribas R, Folkerd E, Liccardi G, Nikitorowicz-Buniak J, Johnston SR, Dowsett M, Martin LA.

Br J Cancer. 2018 Aug;119(3):313-322. doi: 10.1038/s41416-018-0158-y. Epub 2018 Jul 11.

PMID:
29991699
5.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA.

Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.

6.

Optically coupled methods for microwave impedance microscopy.

Johnston SR, Ma EY, Shen ZX.

Rev Sci Instrum. 2018 Apr;89(4):043703. doi: 10.1063/1.5011391.

PMID:
29716321
7.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ.

J Clin Oncol. 2018 Mar 10;36(8):741-748. doi: 10.1200/JCO.2017.74.7824. Epub 2017 Dec 15.

PMID:
29244528
8.

Are Cyclin-dependent Kinase 4/6 Inhibitors Needed for all Oestrogen Receptor-positive Metastatic Breast Cancers?

Johnston SRD.

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):703-706. doi: 10.1016/j.clon.2017.06.016. Epub 2017 Aug 10. No abstract available.

PMID:
28803686
9.

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

Sheri A, Smith IE, Hills M, Jones RL, Johnston SR, Dowsett M.

Breast Cancer Res Treat. 2017 Jul;164(2):395-400. doi: 10.1007/s10549-017-4266-9. Epub 2017 Apr 26.

10.

Fifty important research questions in microbial ecology.

Antwis RE, Griffiths SM, Harrison XA, Aranega-Bou P, Arce A, Bettridge AS, Brailsford FL, de Menezes A, Devaynes A, Forbes KM, Fry EL, Goodhead I, Haskell E, Heys C, James C, Johnston SR, Lewis GR, Lewis Z, Macey MC, McCarthy A, McDonald JE, Mejia-Florez NL, O'Brien D, Orland C, Pautasso M, Reid WDK, Robinson HA, Wilson K, Sutherland WJ.

FEMS Microbiol Ecol. 2017 May 1;93(5). doi: 10.1093/femsec/fix044.

PMID:
28379446
11.

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C.

PLoS Med. 2016 Dec 6;13(12):e1002136. doi: 10.1371/journal.pmed.1002136. eCollection 2016 Dec.

12.

Bacteria in decomposing wood and their interactions with wood-decay fungi.

Johnston SR, Boddy L, Weightman AJ.

FEMS Microbiol Ecol. 2016 Nov;92(11). pii: fiw179. doi: 10.1093/femsec/fiw179. Epub 2016 Aug 23. Review.

PMID:
27559028
13.

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.

Guest SK, Ribas R, Pancholi S, Nikitorowicz-Buniak J, Simigdala N, Dowsett M, Johnston SR, Martin LA.

PLoS One. 2016 Jun 16;11(6):e0157397. doi: 10.1371/journal.pone.0157397. eCollection 2016.

14.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC.

J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6.

PMID:
27269946
15.

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

Li W, O'Shaughnessy J, Hayes D, Campone M, Bondarenko I, Zbarskaya I, Brain E, Stenina M, Ivanova O, Graas MP, Neven P, Ricci D, Griffin T, Kheoh T, Yu M, Gormley M, Martin J, Schaffer M, Zelinsky K, De Porre P, Johnston SR.

Clin Cancer Res. 2016 Dec 15;22(24):6002-6009. Epub 2016 Jun 7.

16.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ.

J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23.

PMID:
27217461
17.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SRD, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC.

Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13.

18.

Targeted Combinations for Hormone Receptor-Positive Advanced Breast Cancer: Who Benefits?

Johnston SR.

J Clin Oncol. 2016 Feb 10;34(5):393-5. doi: 10.1200/JCO.2015.64.0771. Epub 2015 Dec 23. No abstract available.

PMID:
26700117
19.

Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.

Johnston SR.

Lancet. 2016 Feb 27;387(10021):819-21. doi: 10.1016/S0140-6736(15)01219-2. Epub 2015 Dec 11. No abstract available.

PMID:
26686312
20.

Location, location, location: priority effects in wood decay communities may vary between sites.

Hiscox J, Savoury M, Johnston SR, Parfitt D, Müller CT, Rogers HJ, Boddy L.

Environ Microbiol. 2016 Jun;18(6):1954-69. doi: 10.1111/1462-2920.13141. Epub 2016 Jan 21.

PMID:
26626102
21.

Guest-Induced Emergent Properties in Metal-Organic Frameworks.

Allendorf MD, Foster ME, Léonard F, Stavila V, Feng PL, Doty FP, Leong K, Ma EY, Johnston SR, Talin AA.

J Phys Chem Lett. 2015 Apr 2;6(7):1182-95. doi: 10.1021/jz5026883. Epub 2015 Mar 19.

PMID:
26262970
22.

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.

Johnston SR.

J Natl Cancer Inst. 2015 Aug 6;107(10). pii: djv212. doi: 10.1093/jnci/djv212. Print 2015 Oct. Review.

PMID:
26251289
23.

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C.

Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23.

PMID:
26003169
24.

Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunction.

Sharp A, Johnston SR.

Case Rep Oncol. 2015 Feb 26;8(1):113-21. doi: 10.1159/000371720. eCollection 2015 Jan-Apr.

25.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M.

Clin Cancer Res. 2015 Jul 1;21(13):2932-40. doi: 10.1158/1078-0432.CCR-14-1428. Epub 2014 Nov 14.

26.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M.

Ann Oncol. 2015 Jan;26(1):75-80. doi: 10.1093/annonc/mdu508. Epub 2014 Oct 30.

PMID:
25361988
27.

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.

Roylance R, Endesfelder D, Jamal-Hanjani M, Burrell RA, Gorman P, Sander J, Murphy N, Birkbak NJ, Hanby AM, Speirs V, Johnston SR, Kschischo M, Swanton C.

Breast Cancer Res Treat. 2014 Nov;148(1):221-9. doi: 10.1007/s10549-014-3153-x. Epub 2014 Oct 7.

PMID:
25288231
28.

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.

Omarini C, Thanopoulou E, Johnston SR.

Breast Cancer Res Treat. 2014 Jul;146(2):245-58. doi: 10.1007/s10549-014-3016-5. Epub 2014 Jun 15. Review.

PMID:
24929676
29.

Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.

Adjogatse D, Thanopoulou E, Okines A, Thillai K, Tasker F, Johnston SR, Harper-Wynne C, Torrisi E, Ring A.

Clin Oncol (R Coll Radiol). 2014 Nov;26(11):692-6. doi: 10.1016/j.clon.2014.05.002. Epub 2014 Jun 6.

PMID:
24909701
30.

Can NOAH guide us to improved survival in breast cancer?

Johnston SR.

Lancet Oncol. 2014 May;15(6):550-2. doi: 10.1016/S1470-2045(14)70116-0. Epub 2014 Mar 20. No abstract available.

PMID:
24657002
31.

Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer.

Delea TE, Hawkes C, Amonkar MM, Lykopoulos K, Johnston SR.

Breast Care (Basel). 2013 Dec;8(6):429-37. doi: 10.1159/000357316.

32.

The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?

Johnston SR, Yeo B.

Curr Oncol Rep. 2014;16(1):358. doi: 10.1007/s11912-013-0358-9. Review.

PMID:
24390724
33.

Dual HER2 targeting for early breast cancer.

Johnston SR.

Lancet Oncol. 2013 Nov;14(12):1145-6. doi: 10.1016/S1470-2045(13)70463-7. Epub 2013 Oct 4. No abstract available.

PMID:
24095298
34.

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators.

Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29.

35.
36.

Taxane benefit in breast cancer--a role for grade and chromosomal stability.

A'Hern RP, Jamal-Hanjani M, Szász AM, Johnston SR, Reis-Filho JS, Roylance R, Swanton C.

Nat Rev Clin Oncol. 2013 Jun;10(6):357-64. doi: 10.1038/nrclinonc.2013.67. Epub 2013 May 7. Review.

PMID:
23648828
37.

The breast cancer genome and the complexity of different subgroups: what does it all mean?

Johnston SR.

J R Coll Physicians Edinb. 2013;43(1):36. doi: 10.4997/JRCPE.2013.108. No abstract available.

PMID:
23516689
38.

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.

Johnston SR, Gómez H, Stemmer SM, Richie M, Durante M, Pandite L, Goodman V, Slamon D.

Breast Cancer Res Treat. 2013 Feb;137(3):755-66. doi: 10.1007/s10549-012-2399-4. Epub 2013 Jan 3.

PMID:
23283526
39.

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME.

Breast Cancer Res Treat. 2013 Jan;137(2):471-82. doi: 10.1007/s10549-012-2369-x. Epub 2012 Dec 13.

40.

Imaging in oncology--over a century of advances.

Sharma B, Martin A, Stanway S, Johnston SR, Constantinidou A.

Nat Rev Clin Oncol. 2012 Dec;9(12):728-37. doi: 10.1038/nrclinonc.2012.195. Epub 2012 Nov 13. Review.

PMID:
23149892
41.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.

42.

BOLERO-2 - will this change practice in advanced breast cancer?

Johnston SR.

Breast Cancer Res. 2012 Jun 19;14(3):311.

43.

Controversies in adjuvant endocrine therapy for breast cancer.

Johnston SR.

Am Soc Clin Oncol Educ Book. 2012:20-6. doi: 10.14694/EdBook_AM.2012.32.20.

44.
45.

The role of chemotherapy and targeted agents in patients with metastatic breast cancer.

Johnston SR.

Eur J Cancer. 2011 Sep;47 Suppl 3:S38-47. doi: 10.1016/S0959-8049(11)70145-9. Review.

PMID:
21944023
46.

Metastatic breast cancer in a young adult man after total-body irradiation for acute lymphoblastic leukemia.

O'Flynn EA, Wilson R, Nerurkar A, Johnston SR, Allen SD.

J Clin Oncol. 2011 Jul 10;29(20):e607-9. doi: 10.1200/JCO.2011.34.6809. Epub 2011 May 2. No abstract available.

PMID:
21537043
47.

Introduction: are current drug development programmes realising the full potential of new agents?

Johnston SR, Bhatanager A.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S20. doi: 10.1186/bcr2749. No abstract available.

48.

Receptor discordance: does it mean anything?

Johnston SR.

Clin Breast Cancer. 2010 Dec 1;10(6):419-20. doi: 10.3816/CBC.2010.n.066. No abstract available.

PMID:
21147684
49.

Are we missing the mTOR target in breast cancer?

Johnston SR.

Breast Cancer Res Treat. 2011 Aug;128(3):607-11. doi: 10.1007/s10549-010-1207-2. Epub 2010 Oct 16. No abstract available.

PMID:
20953834
50.

Living with secondary breast cancer: coping with an uncertain future with unmet needs.

Johnston SR.

Eur J Cancer Care (Engl). 2010 Sep;19(5):561-3. doi: 10.1111/j.1365-2354.2010.01216.x. No abstract available.

PMID:
20735466

Supplemental Content

Loading ...
Support Center